Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

AstraZeneca Announced Earlier Lynparza Approved in EU for Prostate Cancer; AstraZeneca to Receive $105M Milestone Payment from Merck

By Charles Gross
Today, 8:45 AM
AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the European Union for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men for whom chemotherapy is not clinically indicated.

AZN

Read More
2 minute read

AstraZeneca Earlier Announced Forxiga Recommended for Approval in the EU by CHMP for Symptomatic Chronic Heart Failure

By Charles Gross
Today, 8:45 AM
AstraZeneca's Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) to extend the indication for heart failure with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF) including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF).

AZN

Read More
1 minute read

AstraZeneca Announced Earlier PEARL Phase III Trial of Imfinzi Monotherapy in Stage IV Non-small Cell Lung Cancer Did Not Achieve Statistical Significance for the Primary Endpoints

By Charles Gross
Today, 8:45 AM
The PEARL Phase III trial for AstraZeneca's Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoints of improving overall survival (OS) versus platinum-based chemotherapy as a monotherapy treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC) whose tumour cells express high levels (25% or more) of PD-L1, or in a subgroup of patients at lo

AZN